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Abstract
Background: An increasing number of anticancer agents has been proposed in recent years with the attempt to
overcome treatment-resistant cancer cells and particularly cancer stem cells (CSC), the major culprits for tumour
resistance and recurrence. However, a huge obstacle to treatment success is the ineffective delivery of drugs within
the tumour environment due to limited solubility, short circulation time or inconsistent stability of compounds that,
together with concomitant dose-limiting systemic toxicity, contribute to hamper the achievement of therapeutic
drug concentrations. The synthetic retinoid Fenretinide (4-hydroxy (phenyl)retinamide; 4-HPR) formerly emerged as
a promising anticancer agent based on pre-clinical and clinical studies. However, a major limitation of fenretinide is
traditionally represented by its poor aqueous solubility/bioavailability due to its hydrophobic nature, that
undermined the clinical success of previous clinical trials.
Methods: Here, we developed a novel nano-micellar fenretinide formulation called bionanofenretinide (Bio-nFeR),
based on drug encapsulation in an ion-pair stabilized lipid matrix, with the aim to raise fenretinide bioavailability
and antitumour efficacy.
Results: Bio-nFeR displayed marked antitumour activity against lung, colon and melanoma CSC both in vitro and in
tumour xenografts, in absence of mice toxicity. Bio-nFeR is suitable for oral administration, reaching therapeutic
concentrations within tumours and an unprecedented therapeutic activity in vivo as single agent.
Conclusion: Altogether, our results indicate Bio-nFeR as a novel anticancer agent with low toxicity and high activity
against tumourigenic cells, potentially useful for the treatment of solid tumours of multiple origin.
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Background
Most tumours are heterogeneous and contain a small
population of CSC that are believed to play a crucial role
in tumour progression, drug resistance, recurrence and
metastasis in multiple malignancies [30]. Thus, several
potential approaches to kill therapeutically-resistant CSC
have been deeply explored and, besides overcoming pri-
mary intrinsic resistance of tumour cells, they have been
proved effective against tumour relapse and metastasis,
as well [12, 22]. However, in view of the plasticity of
tumour cells, drugs with broad toxicity against different
tumour cell populations would to be preferred to
achieve long-term antitumour efficacy [40]. Another
huge obstacle to treatment efficacy is the inefficient drug
absorption into the tumour environment mainly due to
low systemic availability which limits the drug distribu-
tion to the different body compartments, including the
tumor. Moreover, the unspecific toxicity of the antitu-
mor drugs strongly restrains dose-escalation as a mean
to improve the systemic availability [45]. Properly de-
signed nanoformulations may offer the possibility of in-
creasing the drug systemic availability, thus improving
the drug concentration at the tumour site to levels suit-
able at eliciting an antitumour response.
In nanoformulations the drug is generally enclosed
in nanostructured materials (nanoparticles) providing
drug aqueous solubilization at extents depending on
the overall characteristic of the system. Based on the
physico-chemical properties of the materials the nanopar-
ticles may be nanomicelles, nanocapsules, nanospheres
etc. [23]. They are mainly administered by oral or intra-
venous route. In intravenous administration the nanopar-
ticle role changes with the tumor characteristics. In
tumors with vascular discontinuities the nanoparticle
function is to transport the drug in circulation avoiding
release until extravasation takes place through the discon-
tinuities of the tumor capillaries where the nanoparticle
accumulation provides increased drug concentration in
the tumor environment with respect to the other body
compartments [18, 25, 34].
In oral administration the nanoparticle role is to in-
crease the drug solubilization and absorption in the
gastrointestinal environment to enhance drug plasma
concentration and biodistribution at suitable levels for
drug activity. The nanoparticles do not cross the gastro-
intestinal wall and lipophilic drugs such as fenretinide
are primarily absorbed by the lipid absorption pathway
mediated by chylomicrons (Barry J. [26]).
Nanoparticles for oral administratioin have been ex-
tensively studied to improve the therapeutic efficacy of
antitumor drugs [11]. Oral lipid nanoparticles, in par-
ticular have been proved to increase solubility, chemical
stability, epithelium permeability and bioavailability of
hydrophobic bioactive compounds [17].
Moreover, lipid nanocarriers offer new possibilities of
obtaining therapeutic drug levels by oral administration,
the most simple and reliable administration route. In-
deed they have been proved to increase solubility, chem-
ical stability, epithelium permeability and bioavailability
of hydrophobic bioactive compounds [17].
Fenretinide (4-HPR) is a synthetic retinoid which emerged
as a promising anticancer agent based on numerous in vitro
and animal studies as well as chemoprevention clinical trials
(B. J. [29, 48, 49]). It is reported to induce cytotoxicity by
multiple mechanisms (Holliday, Cox, Kang, & [27]; B. J. [28,
35, 38, 51, 52]). Significantly, fenretinide has shown the po-
tential to target CSC-associated molecular targets, further
increasing its therapeutic value [1, 10, 33, 53]. An oral for-
mulation of fenretinide, consisting of soft gelatin capsules
containing fenretinide in corn oil and polysorbate, is cur-
rently available at the National Cancer Institute (NCI-FeR).
However, despite promising in vitro cytotoxicity, its antitu-
mour activity in clinical trials (both as a cancer therapeutic
and chemopreventive agent) remains limited, likely due to
poor bioavailability of this drug formulation requiring the
administration of excessively elevated drug doses that con-
strain drug tolerability and patient compliance [3, 4, 15]. Nu-
merous attempts have been made to develop fenretinide
formulations capable of increasing the drug aqueous solubil-
ity and bioavailability to levels that can elicit a satisfactory
therapeutic response. Promising, although still unsatisfactory
results have been obtained in a trial with neuroblastoma
children, while in adult patients (lymphoma) the high drug
doses required to achieve therapeutic plasma drug concen-
trations strongly limited patient compliance causing gastro-
intestinal toxicity and (reversible) nyctalopia. Improved
efficacy of oral fenretinide, when co-administered with other
drugs, has been reported, possibly due to lower drug con-
centration required for synergistic activity or to increased
fenretinide exposure induced by co-administered drugs [4,
8, 20, 27, 37]. Intravenously infused fenretinide as a soy oil-
in-water emulsion showed promising results in patients with
hematologic malignancies [32]. Lastly, all these studies sug-
gested that improved fenretinide formulations are needed to
couple acceptable drug doses, tolerability and patient com-
pliance with significant systemic exposure, aiming at satis-
factory therapeutic efficacy also as single agent treatment for
both adult and pediatric patients.
We recently reported a new fenretinide-cyclodextrin
complex, which has a higher solubility and bioavail-
ability as compared to previous formulations [36].
However such complex requires intravenous adminis-
tration, which limit the potential clinical use of this
drug particularly for extended treatment periods.
Now, we developed a nano-formulation of fenretinide,
called bionanofenretinide (Bio-nFeR) with the aim to
combine a high bioavailability and low toxicity with
the suitability for oral administration.
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We developed a new nano-formulation of fenretinide,
called bionanofenretinide (Bio-nFeR) designed with the
aim to raise the poor oral fenretinide bioavailability, that
has prevented its clinical use in spite of its considerable
antitumour activity and low toxicity profile, until now.
Bio-nFeR is based on ion pair formation between fenreti-
nide and phosphatidylcholine triggering the spontaneous
formation of micelles, in water, containing fenretinide in
their inner core.
Bio-nFeR displayed very promising antitumour activity,
superior than NCI-FeR, against CSC of various origin in
vitro at low concentrations, and in CSC-derived tumour
xenografts of lung, colon and melanoma origin, reaching
higher drug concentration in blood and therapeutic drug
tumour levels within xenografts, in absence of toxicity.
Materials and methods
Chemicals
4-HPR (fenretinide) was purchased from Olon Spa
(Milan Italy). L-α-phosphatidylcholine from egg yolk,
glyceryl tributyrate and all the other chemicals were pur-
chased from Sigma-Aldrich. Deuterated fenretinide
(C26H29D4NO2) used as internal standard (IS), was ob-
tained from Tocris Bioscience (Bristol, UK).
Bio-nFeR preparation
Fenretinide was homogeneously mixed with L-α-phos-
phatidylcholine and glyceryl tributyrate dispersed in al-
kaline ethanol to a final weight ratio 1:9:1 w:w:w
respectively. Ethanol was removed from the mixture in a
rotary evaporator and the dry residue stored at − 18 °C
until use. Reconstitution of the dry residue to Bio-nFeR
nanomicelles was accomplished by dissolving the residue
in water at 30 °C in an ultrasound bath where a wave
frequency of 40 kHz was applied for 1 h to the dissolving
phase. The dissolved residue was subsequently filtered
through 0.4 um pore filters to obtain homogeneously
dispersed nanomicelles of controlled mean size. To com-
pare Bio-nFeR with the soft gelatin capsules representing
the standard formulation most used in clinical trials for
fenretinide, we reconstituted the capsules content ac-
cording to the directions provided by National Cancer
Institute per capsule (fenretinide: 100 mg, corn oil: 704
mg, polysorbate 80: 60 mg). The final concentration in
the reconstituted content of the NCI capsules (NCI-FeR)
being 11.6% w:w fenretinide:internal capsule compo-
nents, as per the NCI instructions.
Solubilization ability, encapsulation efficiency and drug
loading capacity of bio-nFeR towards fenretinide
To evaluate the solubilization ability of Bio-nFeR towards
fenretinide, reconstitution of the dry residue to nanomi-
celles was carried out at concentrations increasing from
50 to 300mg/ml, corresponding to the concentration
range used in this study. After filtration through 0.4 um
pore filters, the nanomicelles were diluted (1:3, v:v) with
an ethanol:water (1:1, v:v) mixture and spectrophotomet-
rically analysed at 364 nm for their fenretinide content. As
a comparison the same evaluation was carried out on
empty nanomicelles prepared by the same procedure. The
encapsulation efficiency was obtained as the ratio between
the drug content in the nanomicelles and the drug loaded
in the dry residue used for the nanomicelles preparation.
The drug loading capacity was calculated as the drug
weight content in the nanomicelles per unit weight of
nanomicelles, obtained by the weight of the freeze-dried
nanomicelle suspensions.
Light scattering characterization of bio-nFeR
Particle size, polydispersity and zeta potential were mea-
sured at 37 °C on nanomicelle dispersions obtained by
reconstitution of the dry residue at 50 mg/ml and diluted
1:100 with water (Malvern Instruments, Worcestershire,
UK). A minimum of 12 measurements per sample were
made. Results were the combination of three 10-min
runs for a total accumulation correlation function time
of 30 min. The results were volume-weighted.
Feneretinide release from bio-nFeR
The release of fenretinide from Bio-nFeR was measured
in three different media: HCl solution (pH 1.2), phos-
phate buffer solution (pH 6.8) and phosphate buffer so-
lution (pH 6.8) containing sodium taurocholate (3.0
mM), to simulate the main physico-chemical character-
istics of the gastrointestinal fluids [19]. The nanomicelles
obtained by reconstitution of the dry residue at 50 mg/
ml were diluted (1:10) with the different media and
placed (1 ml) in a dialysis bag (Mw cutoff 5KD) which
was subsequently sealed and immersed in a receiving
compartment containing water (20 ml) and n-octanol (5
ml). N-octanol was added as a drug-extraction phase
simulating the presence of cell membranes in vivo [31].
The system was thermostated at 37 °C. At increasing
time intervals spectrophotometric analysis in the releas-
ing compartment was carried out as described above.
Confocal microscopy
Images were taken by a FV1000 confocal microscope
(Olympus, Tokyo, Japan), using a (Olympus) plan apo
objective 60× oil A.N. 1,42. Excitation light for fenreti-
nide was obtained by an Argon Ion Laser (488 nm) and
emission was recorded from 495 to 550 nm. Images were
taken also by a Nikon C1s confocal laser scanning
microscope, equipped with a Nikon PlanApo 60, 1.4-NA
oil immersion lens.
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Cell culture, drug treatments and cell viability assay
Patient-derived CSC lines were obtained from primary,
melanoma, glioblastoma, lung and colon cancers and
cultured as previously described [9, 14, 42–44].
For drug treatments and cell viability assays, 3000 cells
were plated in triplicate in 96-well plates and left un-
treated or exposed for 72 h to Bio-nFeR (stock solution
200 mg/ml freshly dissolved in water) or NCI-FeR (20
mg/ml dissolved in corn oil and polisorbate 80). Cell via-
bility was detected with Cell TiterGlo (Promega).
Pharmacokinetic studies
Animals
The experiments were performed in CD1 female mice,
7 weeks of age, (body weight 25 ± 2 g) obtained from
Envigo RMS SrL (Udine, Italy). They were maintained
under specific-pathogen-free conditions with constant
temperature and humidity, according to institutional
guidelines regularly checked by a certified veterinarian.
Animal experimentation was conducted in conformance
with the following laws, regulations, and policies governing
the care and use of laboratory animals: Italian Governing
Law (D. l. 26/2014; Authorization n.19/2008-A issued
March 6, 2008 by the Ministry of Health). Mario Negri In-
stitutional Regulations and Policies providing internal au-
thorizations for persons conducting animal experiments
(Quality Management System Certificate –UNI EN ISO
9001:2008 – Reg. N 86121). The experimental protocol was
reviewed by the Mario Negri Institute Ethical Committee
and approved by the Italian Ministry of Health (Aut. Min.
No 489/2016-Pr).
Drug and formulations
The pharmacokinetics of oral Bio-nFeR was investigated
in comparison to that of the reference formulation NCI-
FeR, after single administration of multiple doses and
after chronic administrations, daily for 2 weeks or bi-
daily for 1 week. Bio-nFeR was reconstituted at 20mg/mL
fenretinide to allow the administration of 200mg/Kg fen-
retinide that corresponded to the highest dose. The doses
of 100, 50 and 10mg/Kg were administered by using serial
dilution of the 20mg/mL solution.
NCI-FeR prepared, as per the NCI instructions, at
11.6% w:w fenretinide:internal capsule components, was
diluted with corn oil to obtain the treatment solutions at
the concentrations of 20, 15 and 10mg/mL, correspond-
ing to the administered doses of 200, 150 and 100mg/Kg
respectively.
Treatments and samples collection. Acute study
The oral pharmacokinetics of Bio-nFeR were investi-
gated in four independent groups of 24 mice, random-
ized to receive different treatment with the following
fenretinide equivalent doses: 10, 50, 100 and 200 mg/Kg.
The drug was administered by oral gavage and after
treatment, blood samples were taken at 15 and 30min
and at 1, 2, 4, 8/10, 24 and 48 h and collected in hepa-
rinized tubes from the retro-orbital plexus of the mice
under isoflurane anesthesia. Mice were then sacrificed
by cervical dislocation and liver, kidney and brain were
removed and immediately frozen in dry-ice for future
determination. To obtain plasma, blood was centrifuged
at 4000 rpm for 10min at 4 °C. To evaluate fenretinide
and metabolites excretion, urine and faeces were col-
lected over a 0–24 h and 24–48 h periods. The collection
was performed in three mice per group of treatment,
individually housed into metabolic cages for urine and
faeces collection. All the biological samples were stored
at − 20 °C until analysis. To compare the absorption of
Bio-nFeR to NCI-FeR and to study the bioavailability,
another independent groups of 24 mice were random-
ized to receive an oral dose of 200 mg/Kg of NCI-FeR.
Blood samples were taken at the time reported above.
Twenty-four hours fractions of urine and faeces were col-
lected in three mice per group of treatment. Plasma and
the other biological specimens were stored at − 20 °C until
analysis. Chronic study: the oral pharmacokinetic of Bio-
nFeR in comparison with NCI-FeR were also investigated
after chronic administrations. Mice were divided in three
independent groups, randomized to receive a single treat-
ment of 150mg/Kg or different repeated treatments of
150mg/Kg, daily for 2 weeks (12 days on and 2 days off),
or 100mg/Kg bi-daily for 1 week (5 days on 2 days off).
Bio-nFeR and NCI-FeR were administered by oral gavage,
collecting blood samples at 0.5, 1, 2, 4, 8/10 and 24 h, the
day of the single treatment and at 0, 1, 2, 4, 8/10, 24 and
48 h after the last dose of both the chronic treatments.
The procedures of blood collection, plasma preparation,
sacrifice of mice and storing of samples were as reported
in acute study. Also during chronic treatment, excretions
of fenretinide and metabolites in urine and faeces were de-
termined collecting the specimens in three mice per
group, both at the start of treatment and at the end of the
repeated administration. All the collected samples were
stored at − 20 °C until analysis.
Drug assay and pharmacokinetic elaboration
The determination of fenretinide in plasma of mice and
the others biological samples was determined according
to a method specifically developed and validated for the
quantification of fenretinide (4-HPR) based on liquid chro-
matography-tandem mass spectrometry (LC–MS/MS)
(manuscript in preparation). The procedure of sample
preparation and quantification can be summarized as
follows. 30 μL aliquot of plasma was added with 3 ng of
deuterated internal standard (2H4 4-HPR), deproteinized by
mean of 90 μL of acetonitrile and centrifuged 5min at
13200 rpm at room temperature. The supernatant was
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recovered and 5 μL injected into a HPLC system (Series 200,
Perkin Elmer, MA, USA). Chromatographic separation was
achieved on a Gemini-C18 column (50mm×2.0mm, 5 μm
particle size; Phenomenex Inc., Torrance, CA, USA) at 32 °C
protected with a Security Guard™ ULTRA cartridges C18.
The detection obtained by Mass spectrometric detection was
carried out on a triple quadrupole API 4000 mass spectrom-
eter (Sciex, MA, USA) equipped with atmospheric pressure
chemical ionization source (APCI) operating in positive ion
mode monitoring the transitions 392.3 > 283.2m/z for 4-
HPR and 396.3 > 283.2m/z for the deuterated internal stand-
ard. To assay study samples, a calibration curve of six points
(range: 1.0–500.00 ng/mL) was prepared in control mouse
plasma assessing the precision and the accuracy of the run
analyzing at the same time a set of freshly prepared quality
controls samples. The Limit Of Quantification of the method
was 1 ng/mL in plasma and urine and 50 ng/g in faeces.
Xenografts generation, antitumour activity studies and
tumour pharmacokinetics of bio-nFeR
Cell suspensions of lung and colon cancer and melanoma
CSC lines were mixed 1:1 with Growth Factor-Reduced
Matrigel (Beckton Dickinsons) and injected subcutaneously
in both flanks of 5-week-old female NOD-SCID (non-obese
diabetic/severe combined immunodeficiency) mice in the
case of colon and melanoma or NSG (non-obese diabetic/
severe combined immunodeficiency gamma chain defi-
cient) mice in the case of lung () (Charles River, Wilming-
ton, MA, USA). For drug treatment, when tumours
reached a mean diameter of 0.5 cm, groups of 6 mice were
randomized into 3 groups and treated with vehicle, with
Bio-nFeR (50,100 or 150mg/kg as described) freshly dis-
solved in sterile water or with the standard formulation
NCI-FeR that reproduce NCI capsule (50 or 100mg/Kg).
Treatments were administered by oral gavage 5 days on
and 2 days off for 3 weeks. Tumours were measured twice a
week using a caliper, and mice were monitored for signs of
drug-induced toxicity and weighed regularly. At the end of
treatments, in a study paralleling the assessment of antitu-
mour activity, tumours and blood samples were collected
for pharmacokinetic and molecular studies 3 hours after
the last drug administration. Collection of blood, plasma
separation and storing were as previously described. Imme-
diately after blood collection mice were sacrificed by cer-
vical dislocation, tumours removed rapidly frozen in liquid
nitrogen and stored in small pieces at − 80 °C for subse-
quent fenretinide determination, protein and lipid analyses.
All procedures were performed with the approval of the
Ethics Committee for Animal Experimentation.
Lipid analyses: HPLC-HRMS
Extracted tissue samples (20 μl) were injected into an Ultra
High Performance Liquid Chromatography (UHPLC) sys-
tem (Ultimate 3000, Thermo). Samples were loaded onto a
Reprosil C18 column (2.0mm× 150mm, 2.5 μm- Dr.
Maisch, Germany) for lipids separation. Chromatographic
separations were achieved at a column temperature of
30 °C; and flow rate of 0.2mL/min. For lipids multi-step
gradient program was used. It started with 8% solvent A
(ddH20, 20mmol L-1 ammonium formiate; pH 5) to 6%
solvent A for 3min than to 2% solvent A for 35min and fi-
nally to 100% solvent B (methanol) in 30min. At the end of
gradient, the column was reconditioned with 8% solvent A
for 5min.
The UHPLC system was coupled online with a mass
spectrometer Q- Exactive (Thermo). The instrument
was used with full scan (FS) and a subsequent data
dependent acquisition (DDA) mode. The settings for
Full scan were as follows: resolution, 70,000; automatic
gain control (AGC) target, 3e6; maximum injection time
(IT), 100 ms; and scan range, m/z 150–2000. The
remaining settings for DDA mode were as follows: reso-
lution, 17,500; AGC target, 1e5; maximum IT, 50 ms;
isolation window, m/z1.0, HCD with stepped normalized
collision energy (NCE), 30. Calibration was performed
before each analysis against positive or negative ion
mode calibration mixes (Piercenet, Thermo Fisher,
Rockford, IL) to ensure sub ppm error of the intact
mass. Lipid identification was performed with Lipid-
Search software (Thermo) that processes LC-MS data, to
make provide accurate lipid identification.
Immunofluorescence and confocal analysis of xenografts
Tumour tissue samples were collected in oct, frozen on
dry ice and stored at − 80 °C until further use. Six mi-
cron tissue sections were cut with cryostat and mounted
on coverslips. Tissue sections were fixed with 2% para-
formaldehyde, permeabilized with 0.1% Triton X-100/
PBS, quenched with 1M glycine in PBS and incubated
with antibodies to KI-67 (Dako, clone MIB-1) followed
by secondary anti-mouse antibody coupled with Alexa
488 (Invitrogen). TUNEL assay was performed using in
situ cell death detection KIT fluorescein (Roche) follow-
ing the manufacturer’s instructions. Nuclei were coun-
terstained with DAPI (Invitrogen) and slides were
permanently mounted. Images were taken by a FV1000
confocal microscope (Olympus, Tokyo, Japan), using a
(Olympus) objective 10×. Excitation light was obtained
by a Laser Dapi 408 nm for DAPI, an Argon Ion Laser
(488 nm) for Alexa 488. DAPI emission was recorded
from 415 to 485 nm, FITC emission was recorded from
495 to 550 nm.
Flow cytometry and aldefluor assay
For flow cytometry, 1 × 105 cells were incubated with the
APC-conjugated monoclonal mouse IgG1 antibody anti
CD44V6 Clone # 2F10 R&D System or negative control
APC-conjugated mouse IgG1 (Ebioscience). Alternatively,
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the equivalent PE-conjugated antibodies were used.
Stained cells were analyzed with a FACScanto flow cyt-
ometer (Becton Dickinson). The stem cell population ex-
pressing ALDH enzymatic activity was detected by means
of the Aldefluor™kit (StemCell Technologies, Vancouver,
BC, Canada), according to the manufacturer’s instructions.
Briefly, 1 × 105 cells were incubated in Aldefluor assay
buffer containing ALDH-substrate for45 min at 37 °C;
negative control cells were stained using identical condi-
tions in the presence of ALDH inhibitor diethylaminoben-
zaldehyde (DEAB). Samples were analyzed by FACScanto
flow cytometer (Becton Dickinson) and the fluorescence
profiles were compared.
Immunoblot analyses
For immunoblotting studies, 20 μg of proteins from each
sample were resolved on 4–12% polyacrylamide gel elec-
trophoresis NuPAGE Bis-Tris (Invitrogen, Carlsbad, CA,
USA) and transferred to nitrocellulose membranes. The
following primary antibodies were used: CD44v6 (VFF-
18) mouse monoclonal (eBioscience™), c-Kit (D13A2)
rabbit polyclonal (Cell Signaling), ALDH1 (clone44/
ALDH) mouse monoclonal (Beckton Dikinsons), BMI1
(D20B7) rabbit polyclonal (Cell Signaling), SOX2 (D6D9)
rabbit polyclonal (Cell Signaling) and β-actin monoclonal
(Sigma-Aldrich) antibodies. Peroxidase-conjugated sec-
ondary antibodies were purchased from Amersham™.
Statistical analysis
Results are expressed as means ± s.d. from an appropri-
ate number of experiments. Differences were analyzed
by ANOVA test using GraphPad Prism v.4.0 for Win-
dows (GraphPad Software, San Diego, CA, USA, www.
graphpad.com) and the threshold for statistical signifi-
cance was set at 0.05. P-values are displayed on the
graphs using a single asterisk for significances ranging
from 0.05 to 0.01, two asterisks for values between 0.01
and 0.001 and three asterisks for values below 0.001.
Results
Bio-nFeR nanomicelles
To increase fenretinide bioavailability a new nanomicel-
lar system was prepared by dissolving phosphatidylcho-
line and glyceryl tributyrate in alkaline ethanol in the
presence of the drug. The alkaline solvent, providing
ionization of the fenretinide phenolic hydroxyl allowed
formation of ion pairs with the choline moiety of the
phosphatidylcholine as a counterion. Subsequent evapor-
ation of ethanol provided a semisolid residue containing
the fenretinide - phosphatidylcholine ion pairs dispersed
in the phospholipid excess-glyceryl tributyrate mixture
(Fig. 1a). The dissolution in water of the evaporated resi-
due provided spherical micelles as shown in Fig. 1 B
reporting optical microscopy images obtained by
dissolution of 100mg/ml of the evaporated residue
before filtration. Indeed, the thermodynamic stability of
the fenretinide-phosphatidylcholine ion pair is the
driving force for the formation of micelles characterized
by a hydrophobic inner core containing fenretinide and
an hydrophilic shell formed by the spontaneous assem-
bling of the phospholipid molecules in water where the
ion bridge stabilizes the core-shell interface [24].
As a comparison the same preparative procedure was
followed by using pure ethanol instead of alkaline
ethanol to prevent fenretinide ionization and ion pair
formation. Fluorescence microscopy images, obtained by
exploiting the spontaneous auto-fluorescence of fenreti-
nide, showed spherical drug localizations inside the mi-
celles prepared by fenretinide ionization, indicating the
drug presence in the micellar inner cores in accordance
with fenretinide-phosphatidylcholine ion pair formation.
Without ionization, on the contrary, concentric drug lo-
calizations were obtained, suggestive of liposome-like
structures with drug entrapment in the lipophilic
phospholipid bilayers (Fig. 1c). The NCI-FeR images
showed coarse aggregates related to lack of drug
solubilization (Fig. 1b). Dynamic light scattering measures
of Bio-nFeR indicated mean sizes in the nanometric scale,
good dimensional polydispersity and a negative zeta poten-
tial (Fig. 1d). The solubilization ability of Bio-nFeR towards
fenretinide, evaluated as the increase in drug concentration
with the increase in nanomicelle concentration, was charac-
terized by a linear trend indicative of a micellar-mode of
drug solubilization (Fig. 1e). In micellar solubilization the
linear trend persists until the micelle concentration become
so high to cause self-aggregation and destabilization. In our
study the linear trend lasted up to the maximum nanomi-
celle concentration evaluated (300mg/ml) providing 25.41
mg/ml fenretinide solubilization, much higher than the
aqueous solubility of the pure drug (1.71 10− 3mg/ml).
The release of fenretinide from the nanomicelles was
very low either at pH 1.2 and pH 6.8 being 8.2 and
21.19% respectively after 72 h. In the presence of sodium
taurocholate, on the contrary, the release was signifi-
cantly improved being 48.45% at 72 h (Fig. 1f). This indi-
cated stability of the Bio-nFeR nanomicelles towards
drug leakage at the different pH of the gastrointestinal
environment and their ability to promote intestinal
lymphatic transport of fenretinide by the bile activated
pathway of lipid absorption [5].
Pharmacokinetic studies of bio-nFeR after acute and
repeated administration
As shown in Fig. 2a, after oral administration of different
doses of Bio-nFeR to mice, 4-HPR achieves plasma
Cmax between 2 and 4 h, it is distributed rapidly and
eliminated with half-life of about 7 h, warranting a drug
plasma exposure up to 48 h at each dose investigated.
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The main derived pharmacokinetic parameters are
listed in Table 1: Cmax and AUC increased proportion-
ally with the doses, indicating that the pharmacokinetic
of Bio-nFeR is not dose dependent in the range of doses
studied as shown in Fig. 2b that reports the correlations
between dose vs Cmax and vs AUC. These results sug-
gest that drug dose could be increased further to reach
superior plasma exposure, eventually enhancing the
therapeutic effect.
Following the pharmacokinetic study of different doses
as acute treatment, pharmacokinetic was investigated in
an extensive comparative study, at therapeutic doses of
Bio-nFeR and NCI-FeR. The two schedules of chronic
administration were well tolerated in mice. No body
weight loss or impaired liver function, were observed in
treated- versus control-mice as carried out evaluating
the hepatic enzymes levels (Additional file 1: Table S1).
The schedules used are highly compatible with in vivo
activity studies. 150 mg/Kg of Bio-nFeR and NCI-FeR
were given as single administration (formally day 1) or
for 2 weeks of daily administration (12 days on, 2 days
off) and the plasma concentration-versus-time profiles of
4-HPR is shown in Fig. 2c. From a visual inspection of
the curves and as indicated by the parameters listed in
the Table 2, it can be seen that the exposure to 4-HPR is
1.3 and 1.6 times higher with oral Bio-nFeR than with
Fig. 1 Illustration of the Bio-nFeR biochemical structure and fluorescence microscopic image of drug-containing micelles. a Schematic
representation of micelles composed of phospholipids in the outer layer and fenretinide in the core. b Aqueous dispersions of Bio-nFeR and NCI-
FeR formulations. (Left) Optical microscopy image of Bio-nFeR micelles in water. (Middle) Confocal image of Bio-nFeR (the same as in the left)
showing the presence of autofluorescent fenretinide within micelles. (Right) Confocal image of NCI-FeR in water forming large aggregates of
insoluble material (Images magnification is 60× and 10 μm scale bar is reported). c Confocal laser scanning images of Bio-nFeR micelles obtained
by fenretinide ionization (left) and micelles obtained by the same procedure but without fenretinide ionization (Images magnification is 60× and
0.1 μm scale bar is reported). d Physico-chemical features of Bio-nFeR micelles. e Solubilization ability of Bio-nFeR towards fenretinide f) In vitro
release of fenretinide from Bio-nFeR micelles in HCl solution (pH 1.2), phosphate buffer solution (pH 6.8) and phosphate buffer solution (pH 6.8)
containing sodium taurocholate (3.0 mM)
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oral NCI-FeR after the first treatment and after the re-
peated treatments, respectively.
In details, following the administrations of Bio-nFeR,
4-HPR reaches Cmax between 2 and 4 h, it is distributed
rapidly and eliminated with a half life (HL) of about 5–6
h achieving adequate plasma exposure up to 48 h after
the last administration. On day one, mean Cmax and
AUC0-24h were 6350 ng/mL and 56,881 ng/mL*h and
after the repeated treatment 6813 ng/mL and 78,608 ng/
mL*h. The last value indicates an increase of 40% of the
plasmatic exposure of 4-HPR after chronic administra-
tion of Bio-nFeR in comparison with day one.
R* = AUCinf ratio of repeated treatments vs acute
treatment normalized per dose.
The elimination of fenretinide takes place mainly by
metabolic process with formation of 4-oxo-4-HPR and
Fig. 2 (A-B) Plasma pharmacokinetic profiles of fenretinide after single oral administration of different Bio-nFeR doses. a Comparison of the fenretinide
plasma concentration decay curves after administration of the indicated Bio-nFeR oral doses. b Cmax and AUC of fenretinide as function of the
administered dose of Bio-nFeR. c-d Pharmacokinetic profile in acute and chronic administration of Bio-nFeR compared to NCI-FeR. c Pharmacokinetic
profile of oral Bio-nFeR in comparison with fenretinide NCI formulation after acute treatment (left) or 2 weeks of chronic treatment (right). d
Pharmacokinetic profile of oral Bio-nFeR and its metabolites as single administration or chronic treatment and its metabolites in the same
samples as in C
Table 1 Bio-nFeR pharmacokinetic parameters
Bio-nFeR pharmacokinetic parameters
Bio-nFer Dose (mg/kg) 10 50 100 200
Cmax (ng/ml) 600.9 3654.7 5340.9 6837.8
Tmax (hr) 2 4 4 2
AUC 0-last (hr*ng/ml) 6745.4 39156.9 66323.6 112957.1
AUC inf (hr*ng/ml) 6812.1 39513.7 66751.7 114227.6
HL (hr) 7.48 7.32 6.49 7.16
Pharmacokinetic parameters analysis in mice after single oral treatment of 4
doses of Bio-nFeR: 10, 50, 100 and 200mg/ /kg. Cmax: maximum plasma
concentration achieved after drug administration; Tmax: time until Cmax is
reached; AUC last: experimental area under the concentration-time curve from
time 0 to the last experimental point measured (Clast); AUC inf: AUC calculated
from 0 to Clast added of the extrapolated portion of the AUC calculated by:
AUCz = Clast/ke; HL: plasma half-life of the terminal phase calculated
by: HL = 0.693/ke.
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MPR and via fecal excretion of the unmodified 4-HPR
and metabolites.
As it can be seen in Additional file 1: Figure S1A reporting
the plasma concentration-time profiles of the metabolites
obtained in the study of multiple doses, 4-oxo-4-HPR and
MPR in comparison to 4-HPR, amounted to about 50 and
15% after Bio-nFeR administration. Similar results were
obtained for NCI-FeR administrations in comparative ex-
periments of the two formulations (Additional file 1:
Figure S1B). The main pharmacokinetic parameters ob-
tained for Bio-nFer metabolites are reported in Additional
file 1: Table S2A, comparison of single vs chronic Bio-
nFer treatment in Fig. 2d and comparison of Bio-nFer vs
NCI in Additional file 1: Table S2B.
A similar metabolic picture was seen during chronic
administrations being the metabolites measurable in
plasma 1 hour after administration and with maximal
exposure at 2–4 h (Fig. 2d). The metabolites disappear
with the same half-life of the parent compound (Add-
itional file 1: Table S3). As seen in the acute study, the
relative percent amount versus 4-HPR of 4-oxo-4-HPR,
known to be 2–4-fold more cytotoxic than 4-HPR, and
of the inactive metabolite MPR, after single and repeated
treatment corresponded to about 50 and 15%, respect-
ively. In addiction we detected the presence of a third
metabolite, DH-4-HPR, previously described by Cooper
et al. [4] that amounted to about 5–7% of the parental
drug. As last consideration on metabolites formation, no
significant differences were recorded in their plasma
AUC between day 1 and day 14 (the metabolites AUCs
increase, but reflect in a proportional way the increase of
AUC of the parent drug), thus indicating that no phenom-
ena of saturation or induction of the metabolism are present
after the chronic treatment (Additional file 1: Table S3).
The fecal excretion of the parent drug and metabo-
lites is reported in Additional file 1: Table S4. After
both studies, the acute treatment at multiple doses
and the chronic one, the proportion of Bio-nFeR and
NCI-FeR eliminated in faeces as unmodified 4-HPR is
comprised in the ranges 2–9%, for 4-oxo-4-HPR 4–
33%, for DH-4-HPR 1–12% and less than 0.1% for
MPR.
The amount of dose recovered in urine is negligible
(≤0.002%) in line with the low polarity of fenretinide and
metabolites (data not shown).
Bio-nFeR exerts increased toxicity against lung CSC in
vitro and exhibits improved plasma exposure
With the aim to determine whether Bio-nFeR was
endowed with valuable antitumour activity, its ability to
affect lung-CSC viability was evaluated in comparison
with the standard oral capsule formulation of fenretinide
(NCI-FeR). Five previously isolated and validated patient-
derived lung-CSC of different subtypes (Squamous Cell
Carcinoma, Adenocarcinoma and Large cell Carcinoma)
[44], were exposed to three different doses of Bio-nFeR or
in parallel to NCI-FeR at the same concentrations. Bio-
nFeR exerted a substantial cytotoxic effect, against all
lung-CSC examined even at low concentrations although
with variable extent in different samples, while more than
95% cells were killed at higher doses in all samples tested.
In contrast, NCI-FeR determined a moderate (40–60%)
reduction in cell viability only at higher doses (10 μM).
More precisely, Bio-nFeR inhibited cell viability to a com-
parable extent than that determined by 10 fold higher
concentration of NCI-FeR within the drug doses range
tested, as visible in MTT assay-derived viability curve.
Moreover, these finding was confirmed by the IC50 values
calculated through a comparative dose response experi-
ment performed on lung CSC that evidenced a 10 fold dif-
ference in IC50 with Bio-nFeR IC50 = 0.72 μM and NCI-
FeR IC50 = 9 μM (Fig. 3a and Additional file 1: Figure S2).
We next examined the antitumour activity of Bio-nFeR
in lung-CSC derived xenografts obtained in NSG immu-
nodeficient mice, in comparison with the standard NCI-
FeR formulation. While NCI-FeR administration (50 mg/
kg) did not substantially affect tumour growth rates
compared to tumours of untreated mice, the same dose
of Bio-nFeR determined a significant inhibition of
tumour growth (Fig. 3b left). Importantly, no signs of
Table 2 Pharmacokinetic comparison of Bio-nFeR and NCI-Fer in single versus chronic treatment
4-HPR dose 150mg/Kg
Single acute treatment 2 weeks of treatment daily
Parameters NCI-FeR Bio-nFeR NCI-FeR Bio-nFeR
Cmax (ng/ml) SD 3456.8 ± 1453.3 6350 ± 4153.9 4306.4 ± 1150.7 6813.3 ± 1200.9
Tmax (hr) 2 2 2 4
AUC inf (hr*ng/ml) 46873.8 59371 53554.7 85378.7
AUC 24 h (hr.*ng/ml) 43257.7 56880.7 45436.7 78608.3
HL (hr) 6.4 5.3 8.3 5.7
R* 1.3 1.6
Pharmacokinetic parameters determination in mice after single oral treatment of Bio-nFeR at dose of 150mg/kg or after 2 weeks treatment, in comparison to the
NCI-FeR formulation
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systemic toxicity (Fig. 3b right) were noticed suggesting that
increased Bio-nFeR doses could be safely explored for fu-
ture experiments, with the aim to further enhance efficacy.
Bio-nFeR displays broad antitumour activity in vitro and
in vivo, is well tolerated and reaches elevated and
pharmacologically active intra-tumour concentrations
Given the marked antitumour activity of Bio-nFeR
against lung cancer cells in vitro and in vivo and the en-
hanced systemic exposure compared to the reference
fenretinide formulation, we next extended the evaluation
of its cytotoxic activity in a wide range of concentrations
against lung, colon cancer, melanoma, sarcoma and glio-
blastoma CSC. Three days exposure to Bio-nFeR deter-
mined a marked inhibition of CSC viability in the
majority of CSC samples of each tumour type tested
(Fig. 4a). Generally, while glioblastoma and sarcoma-CSC
lines resulted more resistant to Bio-nFer treatment, a high
fraction of lung, colon and melanoma CSC lines displayed
promising responsiveness to Bio-nFeR, prompting subse-
quent in vivo studies to assess the drug antitumour activ-
ity in the corresponding xenograft models. Subcutaneous
CSC-derived lung, melanoma and colon tumours were
generated in immunodeficient mice and Bio-nFeR was
orally administered for 3 weeks at 100 (lung cancer and
melanoma) or 150 (colon cancer) mg/kg, based on the
absence of toxicity demonstrated in the previous experi-
ment (Fig. 3b), where lower doses of drug were used.
Tumours of treated mice showed a prominent reduc-
tion of the tumour growth rate, compared to control
tumours (Fig. 4b). Moreover, the drug displayed high
tolerability, as no systemic toxicity was observed, ex-
cept for a minor (8%) weight loss in the higher-dose
mice group (150 mg/kg), in absence of other visible
signs of toxicity (Fig. 4b bottom panels). The lack of
mice toxicity, together with acceptable patient toler-
ability observed when 10 times higher doses have
been administered in clinical trials, suggests that the
maximum tolerated dose has not been achieved under
these experimental conditions and can be safely esca-
lated to further enhance drug amount at the tumour
site and therapeutic efficacy [13].
In line with its antitumour efficacy, described above,
the parallel pharmacokinetic study showed that fenreti-
nide reached highly encouraging concentrations in plasma
(Fig. 4c), higher than that reached in plasma of patients
treated with equivalent doses (300mg/m2 is the equivalent
dose corresponding to 100mg/kg in mice) of the standard
drug or of other improved drug formulations in clinical
trials, both as single or multiple administrations [20, 27].
Importantly, as measured here for the first time in
tumour models, the drug showed pharmacologically
Fig. 3 (a) Cytotoxic activity of Bionanofenretinide (Bio-nFeR) in comparison with standard formulation fenretinide (NCI-FeR) in lung CSC. Lung CSC
were exposed to the indicated drug doses and cell viability was evaluated by CellTiter-Glo after 72 h and indicated as percentage versus control
cells. b Bio-nFeR and NCI-FeR antitumour activity in lung CSC-derived xenografts. (left) Growth curves of lung CSC-derived xenografts in control mice
or mice treated with Bio-nFeR or NCI-FeR at 50 mg/kg dose for the indicated times. Lung CSC sample #136 was used for xenograft generation.
Mean ± S.D. of three independent experiments is shown. **P < 0.01. (right) Table of drug-induced systemic toxicity in the three groups of mice
indicated as percentage of body weight loss (BWL) or number of deaths/total number of mice
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Fig. 4 (a) Cytotoxic activity of different doses of Bio-nFeR in lung cancer, melanoma, colon cancer, glioblastoma and sarcoma CSC in vitro. The
indicated CSC were exposed to 0.1, 0.5, 1, 2, 5, 10, 20 and 30 μM drug doses and cell viability was evaluated by Cell Titer-Glo after 72 h and
indicated as percentage versus control cells. b Bio-nFeR antitumour activity in lung cancer, melanoma and colon cancer CSC-derived xenografts.
(Upper panels) Growth curves of CSC-derived xenografts in control mice or mice treated with Bio-nFeR at 100 (lung cancer and melanoma) or
150 (colon cancer) mg/kg dose for the indicated times. Mean ± S.D. of three independent experiments is shown. *P < 0.05 **P < 0.01. (lower
panels) Table of drug-induced systemic toxicity in the three groups of mice indicated as percentage of body weight loss (BWL) or number of
deaths/total number of mice. c Fenretinide levels in plasma and tumours of the same samples as in B. Fenretinide concentration in plasma and
tumours is expressed in ng/ml and the corresponding μM concentration, as indicated (tumour density is assumed as approximately =1). d
Fenretinide metabolites levels in plasma and tumours of the same samples as in B-C. Fenretinide, 4HPR, OXO-4HPR and DH-4HPR concentration
levels in the indicated plasma and tumours of the same samples as in C
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active intra-tumour concentration (ranging from
1.88 μg/g to 2.23 μg/g, equivalent to 4.8–5.7 μM) at both
drug doses analyzed (Fig. 4c). These concentrations were
superior to those required for cytotoxicity in vitro in
these cell lines (Fig. 4a).
In the tumours analyzed, the three main metabolites of
4-HPR already seen in plasma were detected (Fig. 4d). The
most abundant was 4-oxo-4-HPR, the active one, that
achieved comparable tumour concentrations in the three
different models. These concentrations were in the same
range of those of the parent drug, but since this metabolite
is 2–4 fold more active than 4-HPR, we can speculate that
the in vivo antitumour activity is mainly due to its con-
spicuous presence (Additional file 1: Table S5).
Bio-nFeR antitumour activity is associated with reduced
tumour cell proliferation, apoptosis induction, modulation
of lipid metabolism and decrease of CSC features
To dissect the molecular effects of Bio-nFeR treatment in
vivo, control and treated tumour xenografts were analyzed
for their proliferative index and extent of cell death induc-
tion. As clearly visible in confocal images of tumour tissues
slides in Fig. 5a, the expression of KI-67 was strongly re-
duced in all treated tumours. Moreover, tumours treated
with Bio-nFeR at both doses of 100 and 150mg/kg dis-
played a markedly increased fraction of TUNEL-positive
cells in comparison with controls (Fig. 5b). Thus, Bio-nFeR
induced a marked inhibition of tumour cell proliferation as-
sociated with apoptosis induction, in line with previous re-
ports [2, 8].
Previous reports showed that fenretinide-mediated
cytotoxicity is associated with dysregulation of lipid me-
tabolism. Specifically, fenretinide is able to increase the
intracellular levels of dihydroceramides species by tar-
geting the dihydroceramide desaturase [16, 29, 38, 51].
Liquid chromatography-mass spectrometry (LC-MS),
showed that Bio-nFeR treatment induced a marked in-
crease of dihydroceramide and dihydrosphingolipids
(glucosyldihydroceramide) species (Fig. 5c and Additional
file 1: Figure S3). This effect is more evident for dihydro-
ceramides species with 18 and 16 fatty-acid chains. Con-
versely, saturated ceramides levels were not affected by
Bio-nFeR treatment. In concomitance with the accumula-
tion of long-chain dihydroceramide, we also observed a
significant increase of the intracellular levels of sphinga-
nine in Bio-nFeR-treated tumour xenografts (Fig. 5d).
Based on our previous results, we next confirmed that xe-
nografts derived from the specific CSC lines used were
Fig. 5 Reduction of tumour cell proliferation, apoptosis induction and modulation of lipid metabolism by Bio-nFeR. a Confocal images of KI-67
immunofluorescence of tissue slides from control or Bio-nFeR treated lung cancer, melanoma and colorectal (CRC) cancer xenografts. b TUNEL assay,
showing the levels of apoptosis induction at both doses used (upper panels correspond to 100mg/kg-treated lung cancer xenografts and lower panels to
150mg/kg-treated colon cancer xenografts). c Individual dihydroceramides composition of lung (LC), melanoma (MEL) and colorectal (CRC) tumours
treated with Bio-nFeR at single 100–150mg/Kg administration were identified by acyl chain, normalized to control and plotted as fold change. d The
amount of sphinganine in the same samples as in A and B, normalized to control and plotted as fold change. e Immunoblot analysis of CSC antigens
ALDH1, CD44V6 and Bmi-1 in the indicated control (−) or Bio-nFeR treated (+) xenografts. β-actin blot was used for equal loading control
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heterogeneous and composed by a minor sub-population
of CSC within a majority of differentiated tumour cells
[42, 47, 50]. In fact, flow cytometry analysis for CSC spe-
cific markers confirmed that while aldefluor+ (lung) or
CD44V6+ (melanoma and colon) cells constituted a large
fraction of the CSC culture population in vitro as expected
for a CSC-enriched population, this fraction dramatically de-
creased in the corresponding xenografts (Additional file 1:
Figure S4A). Thus, to determine whether Bio-nFeR treat-
ment was effective against CSC within the tumour, we ana-
lyzed the CSC features of control or Bio-nFeR treated
tumour xenografts, based on the expression of CSC-re-
stricted antigens suitable for each tumour type [7, 9, 21, 41,
42, 44, 46, 47, 50]. We found that xenografts derived from
mice treated with Bio-nFeR displayed decreased expression
of CSC-specific antigens compared to control tumour, dem-
onstrating that drug treatment determined a preferential
CSC targeting within the tumour. Thus, Bio-nFeR tumours
displayed decreased CSC features, implying decreased ag-
gressiveness as compared with control tumour (Fig. 5e and
Additional file 1: Figure S4B).
As we observed that Bio-nFeR was superior than NCI-
FeR at 50 mg/kg dose (Fig. 3) in terms of anti tumour
activity and that increased HPR concentration was de-
tected in plasma of Bio-nFeR treated mice compared to
NCI-FeR treated animals at higher therapeutic doses
(Fig. 2), we next evaluated whether at the dose of 100
mg/kg, therapeutically active for Bio-nFeR, NCI-FeR for-
mulation could reach therapeutic drug levels within
tumour. In a comparative study, in which tumour-bear-
ing mice were treated with the two alternative drug for-
mulations at 100 mg/kg dose, Bio-nFeR confirmed
superior antitumour activity compared to NCI-FeR
(Additional file 1: Figure S5), as well as higher plasma
bioavailability (Fig. 6a). Moreover, in line with these re-
sults, Bio-nFeR treatment determined much higher intra
tumour concentration of 4-HPR and its active metabol-
ite 4-oxo-4-HPR, compared to that reached following
NCI-FeR administration (Fig. 6), demonstrating the
higher tropism of Bio-nFeR also at the tumour level, in
line with its superior anti tumour activity.
Discussion
Cellular and molecular heterogeneity of tumours repre-
sents an obstacle for the achievement of long-term
therapeutic efficacy. Cell fractions endowed with ther-
apy-resistant stem cell-associated features are repre-
sented by CSC, which are themselves a heterogeneous
population characterized by epigenetic and functional
traits rather than specific molecular alterations [6]. Thus,
tumour diversity needs to be accurately considered, to
become an option for cancer therapy. For instance,
specific CSC-properties can be targeted to achieve dur-
able effects and the efficacy of molecularly-targeted
compounds needs to be validated in the CSC compart-
ment to assess its long-term therapeutic benefit. Fur-
thermore, another issue is the necessity to reach
therapeutic drug concentrations at the tumour site to in-
crease drug activity against the more resistant CSC while
reducing systemic toxicity. This aim can be accom-
plished through targeted-delivery of drugs to the tumour
site or through appropriate drug modifications favoring
accumulation at the target site, limiting drug degrad-
ation in the blood or increasing its solubility in body
fluids and in tumour microenvironment.
Here, we explored the activity of a promising anti-tumour
agent, fenretinide, against CSC of different tumours upon
enhancing its antitumour activity through a nanocarrier-
based approach. Fenretinide has been previously proved to
be a promising anticancer agent with ability to affect CSC-
related properties and viability of cell lines of different tu-
mours including medulloblastoma, melanoma, breast and
myeloma cell lines [1, 10, 33, 53]. In contrast, fenretinide
activity in vivo is severely hampered by its hydrophobic
character which restrains its bioavailability and prevents the
achievement of therapeutic drug levels in the body com-
partments. Thus, due to fenretinide potential cytotoxic ac-
tivity against aggressive tumour cells and in view of its
proved negligible systemic toxicity, drug development has
been fostered through drug formulations aimed at improv-
ing its solubility and bioavailability. Encouraging results
have been obtained in this direction, including a fenreti-
nide-cyclodextrin complex developed in our laboratory
which, however, required intravenous administration [36]
([4, 8, 20]; B. J. [27, 32, 37]).
We developed a new nano-micellar fenretinide formu-
lation called bionanofenretinide (Bio-nFeR), based on
ion pair formation between fenretinide and phosphat-
idylcholine. Such pairing triggers the spontaneous for-
mation in water of micelles, containing a fenretinide
inner core and an hydrophilic shell formed by the spon-
taneous assembling of the phospholipid molecules. The
nanomicelles were designed to raise fenretinide solubility
and bioavailability by oral administration and provide
drug levels in the body compartments suitable to elicit a
therapeutic response. To assess the therapeutic potential
of the Bio-nFeR formulation we compared its activity in
vitro and in tumour xenografts with that of the standard
formulation made of soft gelatin capsules containing fen-
retinide in corn oil and polysorbate, which is currently
available at the National Cancer Institute (NCI-FeR) and
has been largely tested in clinical trials [13]. Bio-nFeR
displayed encouraging cytotoxic activity against all lung-
CSC tested and its activity was superior than the stand-
ard NCI-FeR, with more than 10 fold difference in the
IC50 in most cases (Fig. 2a and Additional file 1: Figure
S2). Enhanced antitumour activity was observed in vivo,
as Bio-nFeR proved to be far more effective in the
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growth inhibition of xenografts generated by lung-CSC
(Fig. 4). Importantly, no signs of systemic toxicity were
noticed, in line with the high tolerability described for
patients treated with comparable doses of different for-
mulations in clinical trials and suggesting that increased
Bio-nFeR doses could be safely explored for future ex-
periments, with the aim to further enhance its efficacy.
In line with robust activity in vivo, Bio-nFeR displayed
an improved pharmacokinetic profile than NCI-FeR. In
fact, in contrast to NCI-FeR that showed a dose
dependent pharmacokinetic curve, the pharmacokinetics
of Bio-nFeR was not dose dependent and appeared linear
in the doses range studied (Fig. 2c). These observations
suggest that drug dose could be further increased to
reach superior plasma exposure and enhance the thera-
peutic effect.
Besides lung cancer, Bio-nFeR cytotoxic activity was
evaluated in a wide range of patient-derived CSC sam-
ples of different origin including melanoma, glioblast-
oma, colon cancer and sarcoma. In the context of a
general marked efficacy, only a minority of CSC samples
resulted less sensitive to Bio-nFeR suggesting that the
drug is endowed with broad and prominent CSC-effi-
cacy, even though biomarkers of response might be
helpful to identify the responsive cells. The more prom-
ising drug activity was observed for lung, colon and mel-
anoma tumour-derived CSC and the corresponding
CSC-derived xenografts displayed high sensitivity to Bio-
nFeR treatment (Fig. 4). Based on the lack of toxicity
observed in the first experiments drug doses were esca-
lated up to 100–150 mg/kg, determining improved effi-
cacy with negligible side effects. Bio-nFeR antitumour
activity was associated with reduced tumour cell prolif-
eration, apoptosis induction and modulation of lipid me-
tabolism at both Bio-nFer doses used (Fig. 5). The
fenretinide doses used in mice experiments are compar-
able to the lower range doses used in drug escalation
clinical trials using NCI-FeR or other fenretinide formu-
lations, accordingly to the body surface area conversion
method used to calculate the human equivalent doses
(HED), as previously reported [39]. In fact, as 100 mg/kg
(dose used in mice) is equivalent to 300 mg/m2, and up
to 10 times higher doses were tolerated in clinical trial
patients, it is likely that the drug dose of Bio-nFeR can
be escalated further in absence of substantial side effects
and the therapeutic efficacy correspondingly increased
(the maximum dose used is pediatric cinical trial has
been 4000mg/m2 and displayed manageable toxicity)
[13, 15].
Our pharmacokinetics studies showed that single Bio-
nFeR administration at 100 mg/kg/daily determined high
plasma concentrations, higher than the therapeutic con-
centrations and superior to those found in other mice
studies after both single or chronic administration of the
standard fenretinide formulation (NCI-FeR) or with the
more recently introduced oral powder lipid matrix for-
mulation, called LYM-X-SORB matrix (13.64 μM plasma
concentration was obtained after a single 100mg/kg Bio-
Fig. 6 Comparison of fenretinide levels in blood and tumours of mice treated with standard NCI-FeR or Bio-nFeR formulations. a Fenretinide
concentration (± standard deviation) in plasma (expressed in ng/ml and the corresponding μM concentration are indicated) and tumours (in ng/
g and the extrapolated μM concentration assuming tumour density as approximately = 1) of mice after 3 weeks 100 mg/kg oral administration of
each drug formulation. b Fenretinide metabolites levels in plasma and tumours of the same samples as in A. Fenretinide, 4HPR, OXO-4HPR and
DH-4HPR concentration levels in the indicated plasma and tumours of the same samples as in A
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nFeR administration, versus 1.6 μM reported for NCI-FeR
and 5.1 μM for LYM-X-SORB after repeated administra-
tions of 120mg/kg for 4.5 days) (Barry J. [26]).
Thus, the oral bioavailability has been found to be ac-
ceptable and reproducible in the doses range studied.
Bio-nFeR has showed, at therapeutic doses of fenreti-
nide, higher systemic exposure than that obtained with
the reference NCI formulation, especially during the
chronic pharmacokinetic study conducted after 1 or 2
weeks of daily administration. The high bioavailability
contributed to reach unexpectedly high drug concentra-
tions within tumour tissue in three different models
tested (lung, colon and melanoma) after mice treatment
with Bio-nFeR (Fig. 4c, d). In fact, the new formulation
showed intratumour concentration of fenretinide
pharmacologically active, superior to those required for
cytotoxicity in vitro (Figs. 2a and 3). Finally, intratumour
concentration of 4HPR obtained following Bio-nFeR
treatment was much higher than that obtained with the
standard NCI-FeR administered at the same dose. These
results enforced the assumption that the increased anti-
tumour efficacy of Bio-nFeR in vivo, compared to NCI-
FeR, is the direct consequence of the improved bioavail-
ability obtained with the new formulation that achieved
higher drug concentration at tumour site.
Conclusions
In conclusion, with the aim to explore the possibility of
fully exploit the therapeutic potential of fenretinide, we
generated and tested, for the first time in in vitro and in
vivo models, the anti-tumour activity of fenretinide
nanoencapsulated in a new micellar system, Bio-nFeR, de-
signed to improve its bioavailability and obtain effective
anti-tumour plasma concentrations. Bio-nFeR therapeutic
efficacy was superior to previous formulations and dis-
played negligible systemic toxicity at therapeutic doses.
Our results propose Bio-nFeR as a CSC-effective innova-
tive formulation of fenretinide with increased antitumour
activity in vitro and in vivo due to improved drug solubil-
ity and bioavailability, that guarantees therapeutic drug
exposure at tumour site in the absence of toxicity. Our re-
sults strongly encourage further preclinical-investigation
on Bio-nFer in solid tumour CSC in the direction of
clinical development.
Additional file
Additional file 1: Figure S1. Metabolites plasma concentrations (MPR
and oxo-4-HPR) determined in mice after single oral treatment of 4 doses
of Bio-nFeR: 10, 50, 100 and 200 mg/Kg. The analysis was performed after
0, 24, 48 h. Figure S2. Evaluation of the 50% inhibitory concentration
(IC50) of BionFeR and NCI-FeR formulation was done on a representative
lung cancer stem cell line (LCSC). The cells were exposed to the
indicated drug doses (0–30 μM) and cell viability was evaluated by
CellTiter-Glo after 72 h. Figure S3. A) Sphingomyelin-Ceramide (SM-CER)
and Sphingomyelin- Dihydro-Ceramide (SM-DH-CER) content in lung (LC),
melanoma (MEL) and colon (CRC) tumors treated with Bio-nFeR at single
100–150 mg/Kg administration were quantified through Ultra High
Performance Liquid Chromatography (UHPLC), normalized to control and
plotted as fold change. B) Quantification of Glucosyl-Ceramide (GLC-CER)
and Glucosyl-Dihydro-Ceramide (GLC-DH-CER) in the same samples as in
A, normalized to control and plotted as fold change. Figure S4. Cancer
stem cell marker expression in CSC-culture conditions and in CSC-derived
xenografts. A) Flow cytometry analysis of Aldefluor in (left panels) and
CD44v6 (middle and right panels) in the indicated CSC and xenograft
samples. B) Immunoblot analysis of CSC antigens c-Kit and SOX-2 in the
indicated control (−) or BionFeR treated (+) melanoma xenografts. β-actin
blot was used for equal loading control. Figure S5. Growth curves of
lung CSC-derived xenografts in control mice or mice treated with Bio-
nFeR or NCI-FeR at 100 mg/kg dose for the indicated times. Mean ±
standard error is shown. *P < 0.05. Table S1. Hepatic enzyme
determination in mice after single administration or 2 weeks oral daily
treatment at dose of 150 mg/kg of Bio-nFeR or NCIFeR formulation. AST:
Aspartate transaminase; ALT: Alanine transaminase; Bil tot: Bilirubin total;
Vehicle after 24 h. Table S2. Quantification of 4-HPR and metabolites
(oxo-4-HPR e MPR) determined in mice after oral Bio-nFeR single
treatment of BNF: 10, 50, 100 and 200 mg/Kg (A) or Bio-nFer at dose of
200 mg/kg in comparison to the NCI-FeR formulation (B). Cmax:
maximum plasma concentration achieved after drug administration;
Tmax: time until Cmax is reached; AUC last: experimental area under the
concentration-time curve from time 0 to the last experimental point
measured (Clast); HL: plasma half-life of the terminal phase calculated by:
HL = 0.693/ke. Table S3. 4-HPR and metabolites (oxo-4-HPR, MPR and
DH-4-HPR) evaluated after oral Bio-nFeR single (day 1) or repeated daily
treatment at dose of 150 mg/kg. Cmax: maximum plasma concentration
achieved after drug administration; Tmax: time until Cmax is reached;
AUC last: experimental area under the concentration-time curve from
time 0 to the last experimental point measured (Clast); HL: plasma half-
life of the terminal phase calculated by: HL = 0.693/ke. Table S4. 4-HPR
and metabolites concentrations measured after 24 h in feces of mice
after acute treatment at different doses of Bio-nFeR (10, 50, 100 and 200
mg/Kg) (A) and after chronical treatment at dose of 150 mg/kg (B), in
comparison with the NCI-FeR formulation. Table S5. 4-HPR and
metabolites (MPR, oxo-4-HPR and DH-4-HPR) concentrations in plasma
and tumors (lung cancer, melanoma and colon cancer) as in Fig. 4 BC.
(PDF 308 kb)
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